Virtu Financial LLC purchased a new stake in shares of Davita Inc (NYSE:DVA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,099 shares of the company’s stock, valued at approximately $262,000.
Other large investors have also made changes to their positions in the company. Contravisory Investment Management Inc. boosted its position in shares of Davita by 8.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 3,932 shares of the company’s stock worth $202,000 after purchasing an additional 298 shares in the last quarter. CenturyLink Investment Management Co lifted its position in Davita by 3.5% in the 4th quarter. CenturyLink Investment Management Co now owns 18,187 shares of the company’s stock valued at $936,000 after acquiring an additional 612 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Davita by 10.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 8,168 shares of the company’s stock valued at $585,000 after acquiring an additional 757 shares in the last quarter. Northstar Group Inc. lifted its position in Davita by 7.8% in the 3rd quarter. Northstar Group Inc. now owns 11,684 shares of the company’s stock valued at $837,000 after acquiring an additional 850 shares in the last quarter. Finally, IFM Investors Pty Ltd lifted its position in Davita by 13.0% in the 3rd quarter. IFM Investors Pty Ltd now owns 7,958 shares of the company’s stock valued at $570,000 after acquiring an additional 915 shares in the last quarter. Institutional investors own 85.99% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Royal Bank of Canada reiterated a “hold” rating and set a $65.00 target price on shares of Davita in a research note on Wednesday, January 9th. UBS Group upgraded shares of Davita from a “sell” rating to a “neutral” rating and decreased their target price for the company from $64.00 to $59.00 in a research note on Tuesday, January 8th. Deutsche Bank initiated coverage on Davita in a research note on Thursday, January 3rd. They issued a “buy” rating and a $60.00 price objective for the company. ValuEngine lowered Davita from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Finally, Barclays started coverage on Davita in a research note on Friday, December 14th. They issued an “overweight” rating and a $70.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Davita presently has an average rating of “Hold” and an average target price of $68.35.
Davita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, February 13th. The company reported $0.90 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.90. The business had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.97 billion. Davita had a net margin of 5.39% and a return on equity of 13.87%. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 earnings per share. On average, sell-side analysts predict that Davita Inc will post 3.56 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.